Cullinan Therapeutics is a biopharmaceutical company specializing in the development of transformative therapeutics for oncology and autoimmune diseases. The company has assembled a diverse portfolio of clinical-stage assets designed to address key drivers of these diseases by either inhibiting them or harnessing the immune system to eliminate diseased cells. With a deep commitment to scientific excellence, Cullinan Therapeutics emphasizes a rigorous development process, utilizing advanced translational medicine and immunology to create targeted therapies with the potential to be first in class. The company operates with a focus on innovation, quality, and collaboration, ensuring that only the most promising therapeutic candidates progress through the development pipeline. Cullinan Therapeutics aims to improve patient outcomes by redefining standards of care and delivering effective treatment options to those in need.